Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer

被引：0

作者：

Gallen, M ^{[1
]}

Alonso, C ^{[1
]}

Ojeda, B ^{[1
]}

Viladiu, P ^{[1
]}

Beltran, M ^{[1
]}

Borras, J ^{[1
]}

Pelegri, A ^{[1
]}

Tusquets, I ^{[1
]}

Barnadas, A ^{[1
]}

Arcusa, A ^{[1
]}

Bastus, R ^{[1
]}

Balil, A ^{[1
]}

Batiste-Alentorn, E ^{[1
]}

Boleda, M ^{[1
]}

Badia, MA ^{[1
]}

Garau, I ^{[1
]}

Guash, I ^{[1
]}

机构：

[1] Hosp Mar, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷

关键词：

D O I：

10.1016/S0959-8049(97)89318-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P101

引用

页码：S40 / S40

页数：1

共 50 条

[41] Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M
Buzdar, AU
Cuzick, J
Forbes, J
Houghton, J
Klijn, JGM
Sahmoud, T
LANCET, 2002, 359 (9324): : 2131 - 2139
[42] Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14
Pritchard, Kathleen I.
Shepherd, Lois E.
Chapman, Judith-Anne W.
Norris, Brian D.
Cantin, Jacques
Goss, Paul E.
Dent, Susan F.
Walde, David
Vandenberg, Ted A.
Findlay, Brian
O'Reilly, Susan E.
Wilson, Carolyn F.
Han, Lei
Piura, Ettie
Whelan, Timothy J.
Pollak, Michael N.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (29) : 3869 - 3876
[43] ADJUVANT CMFVP VERSUS TAMOXIFEN VERSUS CONCURRENT CMFVP AND TAMOXIFEN FOR POSTMENOPAUSAL, NODE-POSITIVE, AND ESTROGEN RECEPTOR-POSITIVE BREAST-CANCER PATIENTS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
RIVKIN, SE
GREEN, S
METCH, B
CRUZ, AB
ABELOFF, MD
JEWELL, WR
COSTANZI, JJ
FARRAR, WB
MINTON, JP
OSBORNE, CK
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2078 - 2085
[44] Pharmacogenomic prediction of breast cancer treatment outcome with adjuvant tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer
Pribylova, O.
Petruzelka, L. B.
Argalaczova, S.
Konopasek, B.
Drazdakova, J.
Slanar, O.
Slanar, O.
Zima, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[45] RANDOMIZED TRIAL TO EVALUATE THE ADDITION OF TAMOXIFEN TO CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, PREDNISONE ADJUVANT THERAPY IN PREMENOPAUSAL WOMEN WITH NODE-POSITIVE BREAST-CANCER
INGLE, JN
EVERSON, LK
WIEAND, HS
CULLINAN, SA
WOLD, LE
HAGEN, JB
MARTIN, JK
KROOK, JE
FITZGIBBONS, RG
FOLEY, JF
AHMANN, DL
PFEIFLE, DM
GREEN, SJ
CANCER, 1989, 63 (07) : 1257 - 1264
[46] The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women.
Baum, M
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 210 - 210
[47] Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
Fallowfield, L
Cella, D
Cuzick, L
Francis, S
Locker, G
Howell, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4261 - 4271
[48] EFFECTS OF TAMOXIFEN ON UTERUS AND OVARIES OF POSTMENOPAUSAL WOMEN IN A RANDOMIZED BREAST-CANCER PREVENTION TRIAL
KEDAR, RP
BOURNE, TH
POWLES, TJ
COLLINS, WP
ASHLEY, SE
COSGROVE, DO
CAMPBELL, S
LANCET, 1994, 343 (8909): : 1318 - 1321
[49] Updated results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: SITAM-01
Belfiglio, Maurizio
Valentini, Miriam
Pellegrini, Fabio
De Berardis, Giorgia
Franciosi, Monica
Rossi, Maria C. E.
Sacco, Michele
Nicolucci, Antonio
ANNALS OF ONCOLOGY, 2005, 16 : 7 - 7
[50] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004)
Coombes, R. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16): : 1746 - 1746

← 1 2 3 4 5 →